Nemorubicin
| Title | Journal |
|---|---|
| Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. | Scientific reports 20140101 |
| MicroRNA gene dosage alterations and drug response in lung cancer. | Journal of biomedicine & biotechnology 20110101 |
| Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men10755. | Bioorganic & medicinal chemistry 20100215 |
| Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. | Molecular cancer 20100101 |
| Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. | Cancer gene therapy 20090501 |
| In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes. | Biochemical pharmacology 20080915 |
| Ongoing phase I and II studies of novel anthracyclines. | Cardiovascular toxicology 20070101 |
| Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050215 |
| Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. | Molecular pharmacology 20050101 |
| LC-MS-MS determination of nemorubicin (methoxymorpholinyldoxorubicin, PNU-152243A) and its 13-OH metabolite (PNU-155051A) in human plasma. | Journal of pharmaceutical and biomedical analysis 20021015 |
| Nucleotide-induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells. | FEBS letters 20010323 |